← Back to Treatments
🏅 FDA Orphan Designation

Waskyra

etuvetidigene autotemcel

Manufacturer: Fondazione Telethon ETS

Indicated for:
Wiskott-Aldrich syndromeOrphan

FDA-Approved Indications (1)

Wiskott-Aldrich syndromeOrphan Designation

treatment of pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene and for whom hematopoietic stem cell transplantation (HSCT) i

Indications & Usage

treatment of pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene and for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available

💙 Support Programs

View all →
Waskyra
Fondazione Telethon ETS

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.